Latest news with #JNJ
CNBC
17 hours ago
- Business
- CNBC
Health care stocks are due for a turnaround after a historically bad month, according to the charts
The Health Care Select Sector SPDR Fund (XLV) was down over 5% in May, as the S & P 500 gained over 6%, which means that XLV underperformed the index by 11%. That's a huge performance discrepancy. In fact, it was the worst relative monthly percent move vs. the SPX in XLV's history, dating back to late 1998. As is clear from this long-term chart, the odds of this horribly bad relative weakness continuing at this same pace is low – at least for June. XLV itself now has approached two major long-term support levels after the recent downturn. The first is the rising trendline that begins at the 2009 financial crisis low and extends through the Covid bottom. XLV tested this line in mid-May, bounced and finished the month modestly off its lows. The second key support zone comes from the cluster of lows in 2021, 2022 and 2023, noted by the horizontal line that's in the low 120s. The converging lines present a confluence of support that clearly could help XLV's bouncing prospects in June. XLV: The 3 biggest holdings Believe it or not, 34 of XLV's 61 components actually logged gains in May. That's encouraging, but we'll need to see its biggest holdings respond soon. If they can't rally, XLV will continue to struggle. The three largest stocks within the ETF are Eli Lilly , Johnson & Johnson and AbbVie , which make up nearly 27% of XLV combined. So, what are the odds that all three stocks actually can mount strong up-moves in June? Let's take a closer look. We'll start with LLY since it's XLV's biggest component, with a 12% weighting. LLY last made an all-time high in August 2024. From that peak to its April low, the stock lost 30%. But as the following weekly chart (in log scale) shows, it wasn't straight down from there. LLY logged various rallies and drawdowns since then, all of which have taken place within the pictured downward sloping trading channel. The best time to buy LLY, thus, has been after a big, long decline. The stock just fell another 20% from April 30 through May 25. As we can see, the past ensuing bounces yielded big percentage moves, even if they ultimately failed to break through the channel's upper threshold. Additionally, LLY's weekly Williams %R indicator (on the lower panel) is emerging from an oversold condition, which has supported three of the last four big up-moves. In fact, LLY quietly has logged gains in six of the last seven trading days. That's a good start. JNJ (7.7% weight) has been trending lower since topping in 2022, while ABBV (6.8%) has been in a clear uptrend the last few years. However, both have experienced various swings within their respective long-term trading channels — like LLY. And with both JNJ and ABBV having sold off from their 2025 highs, now would be an opportune time for the next bounce to commence. From a big picture market perspective, rotation is an important component of true, long-lasting uptrends. Thus, if/when the air comes out of the more extended sectors and groups soon, capital could find its way to the underperforming areas, which of course, includes health care. DISCLOSURES: None. All opinions expressed by the CNBC Pro contributors are solely their opinions and do not reflect the opinions of CNBC, NBC UNIVERSAL, their parent company or affiliates, and may have been previously disseminated by them on television, radio, internet or another medium. THE ABOVE CONTENT IS SUBJECT TO OUR TERMS AND CONDITIONS AND PRIVACY POLICY . THIS CONTENT IS PROVIDED FOR INFORMATIONAL PURPOSES ONLY AND DOES NOT CONSITUTE FINANCIAL, INVESTMENT, TAX OR LEGAL ADVICE OR A RECOMMENDATION TO BUY ANY SECURITY OR OTHER FINANCIAL ASSET. THE CONTENT IS GENERAL IN NATURE AND DOES NOT REFLECT ANY INDIVIDUAL'S UNIQUE PERSONAL CIRCUMSTANCES. THE ABOVE CONTENT MIGHT NOT BE SUITABLE FOR YOUR PARTICULAR CIRCUMSTANCES. BEFORE MAKING ANY FINANCIAL DECISIONS, YOU SHOULD STRONGLY CONSIDER SEEKING ADVICE FROM YOUR OWN FINANCIAL OR INVESTMENT ADVISOR. Click here for the full disclaimer.
Yahoo
29-05-2025
- Business
- Yahoo
Johnson & Johnson (JNJ) Stock Moves -0.54%: What You Should Know
In the latest trading session, Johnson & Johnson (JNJ) closed at $152.43, marking a -0.54% move from the previous day. The stock outperformed the S&P 500, which registered a daily loss of 0.56%. Meanwhile, the Dow experienced a drop of 0.58%, and the technology-dominated Nasdaq saw a decrease of 0.51%. The world's biggest maker of health care products's stock has dropped by 1.71% in the past month, exceeding the Medical sector's loss of 2.25% and lagging the S&P 500's gain of 7.37%. The upcoming earnings release of Johnson & Johnson will be of great interest to investors. The company is predicted to post an EPS of $2.65, indicating a 6.03% decline compared to the equivalent quarter last year. Alongside, our most recent consensus estimate is anticipating revenue of $22.77 billion, indicating a 1.42% upward movement from the same quarter last year. JNJ's full-year Zacks Consensus Estimates are calling for earnings of $10.60 per share and revenue of $91.19 billion. These results would represent year-over-year changes of +6.21% and +2.66%, respectively. It's also important for investors to be aware of any recent modifications to analyst estimates for Johnson & Johnson. Recent revisions tend to reflect the latest near-term business trends. Hence, positive alterations in estimates signify analyst optimism regarding the company's business and profitability. Empirical research indicates that these revisions in estimates have a direct correlation with impending stock price performance. To utilize this, we have created the Zacks Rank, a proprietary model that integrates these estimate changes and provides a functional rating system. The Zacks Rank system, which ranges from #1 (Strong Buy) to #5 (Strong Sell), has an impressive outside-audited track record of outperformance, with #1 stocks generating an average annual return of +25% since 1988. Within the past 30 days, our consensus EPS projection has moved 0.04% higher. Johnson & Johnson is holding a Zacks Rank of #3 (Hold) right now. In terms of valuation, Johnson & Johnson is presently being traded at a Forward P/E ratio of 14.45. This indicates a premium in contrast to its industry's Forward P/E of 13.26. Also, we should mention that JNJ has a PEG ratio of 2.32. The PEG ratio bears resemblance to the frequently used P/E ratio, but this parameter also includes the company's expected earnings growth trajectory. As of the close of trade yesterday, the Large Cap Pharmaceuticals industry held an average PEG ratio of 1.23. The Large Cap Pharmaceuticals industry is part of the Medical sector. This industry, currently bearing a Zacks Industry Rank of 41, finds itself in the top 17% echelons of all 250+ industries. The Zacks Industry Rank assesses the vigor of our specific industry groups by computing the average Zacks Rank of the individual stocks incorporated in the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1. Ensure to harness to stay updated with all these stock-shifting metrics, among others, in the next trading sessions. Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Johnson & Johnson (JNJ) : Free Stock Analysis Report This article originally published on Zacks Investment Research ( Zacks Investment Research Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Epoch Times
27-05-2025
- Business
- Epoch Times
Poking the Bear: What to Invest in During a Bear Market
Market swings are part of an investor's life. But what happens when the stock market takes a nosedive? What do you do when we fall into bear market territory? This is when a major stock market index like the S&P 500 suffers a decline of 20 percent or more from a previous high. But don't panic. Bear markets could open the door to some investing opportunities and more ways to diversify your portfolio. So here are some tips on where to stash your money during a bear market. Defensive Stocks Defensive stocks are shares of companies that provide essential goods and services that are in demand regardless of where we are in the market cycle. Many of these companies are known to remain resilient and even thrive under bear markets. Here are some examples of defensive sectors. Consumer Staples These are companies that provide food and common household products. Here are some of the top consumer staple stocks: Procter & Gamble Co. (PG) Coca-Cola Co (KO) PepsiCo Inc (PEP) Walmart Inc. (WMT) Costco Wholesale Corp (COST) Health Care This sector includes companies providing pharmaceuticals and medical supplies and equipment, as well as hospitals and long-term care facilities. It also includes biotechnology. Here are some of the top healthcare stocks: Johnson & Johnson (JNJ) Eli Lilly and Company (LLY) Pfizer Inc. (PFE) UnitedHealth Group (UNH) Abbott Laboratories (ABT) Utilities These companies provide electricity, power, and gas to communities across the country. Here are some of the top utilities stocks: NextEra Energy Inc (NEE) The Southern Company (SO) Dominion Energy Inc. (D) Duke Energy Corp. (DUK) Constellation Energy Corporation (CEG) Dividend-Paying Stocks Some companies pay portions of their earnings to shareholders on a regular basis in the form of dividends. So even in a bear market, these companies could provide a steady stream of income. Related Stories 4/22/2025 4/24/2025 Dividends are typically paid on a quarterly basis. The amount is determined by the firm's board of directors and based on the company's recent profits. You would want to look for companies with a history of strong earnings. Here are some notable dividend-paying stocks: ExxonMobil (XOM) Johnson & Johnson (JNJ) Alphabet (GOOG) NextEra Energy (NEE) PepsiCo PEP ConocoPhillips COP Bonds Bonds are essentially loans that you extend to corporations and governments. Bond prices often move in the opposite direction from stock prices. You may want to seek out investment-grade, short-term bonds to diversify your portfolio. You could also consider Treasury securities. These are debt investments issued by the U.S. government, and they are backed by the full faith of Uncle Sam—making them some of the safest investments around. Here are some examples. Treasury bonds : T-bonds are long-term bonds that pay a fixed interest or coupon payment every six months. They mature in 20 years or 30 years. Treasury notes : T-notes pay interest payments every six months. You can purchase T-notes in two-, three-, five-, seven-, and 10-year terms. Treasury bills : You buy T-bills at a discount to their face value. When the bond matures, you get the note's face value. The difference is essentially your interest payment. You can buy Treasury bills with maturities of four, eight, 13, 17, 26, and 52 weeks. Don't Panic Seeing your portfolio plummet during a bear market could tempt you to sell all your stocks. But that means you'd lock in losses and miss out on gains when the market recovers. And it will. Bear markets don't last forever. The typical bear market lasts an average of 9.6 months, according to an analysis by Rebalance Your Portfolio A bear market may be a good time to revisit and rebalance your portfolio. Your stocks may have taken a nosedive while your bonds could have seen significant gains. This would throw your asset allocation off balance and open you to risk. So you may want to sell some stocks and buy more bonds to shift the portfolio back in balance. The Bottom Line Bear markets are scary things. It can be depressing to see your portfolio take a plunge. But don't panic sell and lock in losses before the next bull market. Remember, bear markets are temporary. And you can also find investment opportunities in bear markets. You can look into defensive sector stocks, dividend-paying stocks, and bonds to get started. But overall, it's important to maintain a well-diversified portfolio aligned with your goals in any part of the market cycle. The Epoch Times copyright © 2025. The views and opinions expressed are those of the authors. They are meant for general informational purposes only and should not be construed or interpreted as a recommendation or solicitation. The Epoch Times does not provide investment, tax, legal, financial planning, estate planning, or any other personal finance advice. The Epoch Times holds no liability for the accuracy or timeliness of the information provided.
Yahoo
23-05-2025
- Business
- Yahoo
Johnson & Johnson (JNJ) Declines More Than Market: Some Information for Investors
The latest trading session saw Johnson & Johnson (JNJ) ending at $152.51, denoting a -0.44% adjustment from its last day's close. The stock trailed the S&P 500, which registered a daily loss of 0.04%. The the stock of world's biggest maker of health care products has fallen by 1.42% in the past month, lagging the Medical sector's gain of 1.44% and the S&P 500's gain of 13.42%. Market participants will be closely following the financial results of Johnson & Johnson in its upcoming release. In that report, analysts expect Johnson & Johnson to post earnings of $2.65 per share. This would mark a year-over-year decline of 6.03%. Meanwhile, our latest consensus estimate is calling for revenue of $22.77 billion, up 1.42% from the prior-year quarter. Regarding the entire year, the Zacks Consensus Estimates forecast earnings of $10.60 per share and revenue of $91.19 billion, indicating changes of +6.21% and +2.66%, respectively, compared to the previous year. Investors should also pay attention to any latest changes in analyst estimates for Johnson & Johnson. Recent revisions tend to reflect the latest near-term business trends. As such, positive estimate revisions reflect analyst optimism about the company's business and profitability. Empirical research indicates that these revisions in estimates have a direct correlation with impending stock price performance. We developed the Zacks Rank to capitalize on this phenomenon. Our system takes these estimate changes into account and delivers a clear, actionable rating model. The Zacks Rank system, running from #1 (Strong Buy) to #5 (Strong Sell), holds an admirable track record of superior performance, independently audited, with #1 stocks contributing an average annual return of +25% since 1988. Over the past month, there's been a 0.04% rise in the Zacks Consensus EPS estimate. Johnson & Johnson is currently a Zacks Rank #3 (Hold). Looking at valuation, Johnson & Johnson is presently trading at a Forward P/E ratio of 14.45. This valuation marks a premium compared to its industry's average Forward P/E of 13.21. It is also worth noting that JNJ currently has a PEG ratio of 2.32. The PEG ratio is akin to the commonly utilized P/E ratio, but this measure also incorporates the company's anticipated earnings growth rate. As the market closed yesterday, the Large Cap Pharmaceuticals industry was having an average PEG ratio of 1.21. The Large Cap Pharmaceuticals industry is part of the Medical sector. This industry, currently bearing a Zacks Industry Rank of 40, finds itself in the top 17% echelons of all 250+ industries. The Zacks Industry Rank is ordered from best to worst in terms of the average Zacks Rank of the individual companies within each of these sectors. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1. Ensure to harness to stay updated with all these stock-shifting metrics, among others, in the next trading sessions. Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Johnson & Johnson (JNJ) : Free Stock Analysis Report This article originally published on Zacks Investment Research ( Zacks Investment Research Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
21-05-2025
- Business
- Yahoo
Johnson & Johnson (NYSE:JNJ) Hit with $147M Verdict in Landmark Antitrust Case Over Reprocessed Medical Devices
A federal jury in Santa Ana has ordered Johnson & Johnson (NYSE:JNJ) to pay $147 million after its Biosense Webster unit was found guilty of violating antitrust laws. The court ruled J&J illegally withheld clinical support from hospitals using FDA-approved reprocessed catheters, directly undermining competition in the single-use device (SUD) market. A medical technician holding the instruments in her hands Plaintiff Innovative Health secured the major win, exposing Johnson & Johnson (NYSE:JNJ)'s alleged effort to block lower-cost, eco-friendly alternatives. The Association of Medical Device Reprocessors (AMDR) hailed the decision as a breakthrough for hospitals, patients, and sustainability efforts. Johnson & Johnson (NYSE:JNJ) responded with disappointment, claiming its actions were pro-competitive and aimed at ensuring patient safety. The company is weighing an appeal. The landmark verdict casts a spotlight on original equipment manufacturers' (OEMs) market tactics and could trigger wider regulatory scrutiny across the medtech industry. JNJ is up by nearly 7% in 2025 so far. While we acknowledge the potential of JNJ to grow, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and have limited downside risk. If you are looking for an AI stock that is more promising than JNJ and that has 100x upside potential, check out our report about this READ NEXT: and Disclosure: None. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
